Organon & Co | OGN - Net Income



Organon & Co reported $145M in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
Adcock Ingram Holdings ZAR 389.71M 19.87M Dec/2024
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Celltrion KRW 108.67B 127.98B Mar/2025
Cspc Pharmaceutical CNY 1.48B 927.97M Mar/2025
Dianthus Therapeutics USD -31629000 3.19M Jun/2025
Divis Laboratories Ltd 5.45B 1.17B Jun/2025
Gilead Sciences USD 1.96B 645M Jun/2025
Glaxosmithkline GBP 1.44B 1.03B Jun/2025
Kangmei Pharma CNY 8.4M 110.17K Jun/2025
Knight Therapeutics CAD 85K 2.03M Sep/2024
Laboratorios Farma EUR 21.64M 70.9M Jun/2025
Malin Corporation EUR 0 0 Dec/2024
Medical Developments International AUD 304K 15.32M Dec/2024
Merck USD 4.43B 652M Jun/2025
Neuren Pharmaceuticals AUD 134.03M 126.01M Dec/2024
Novartis USD 4.04B 1.22B Jun/2025
Organigram Holdings CAD -6290000 16.67M Jun/2025
Organon & Co USD 145M 58M Jun/2025
Pharma Mar EUR 23.37M 27.32M Jun/2025
Qiagen NV USD 96.25M 5.49M Jun/2025
Sartorius EUR 32.5M 15.9M Jun/2025
Sino Biopharmaceutical CNY 482.67M 2.53B Dec/2024
Tilray USD -85342000 46.18M Nov/2024